Similar results were seen with VL mutations, whereby patients with IBD treated with anti-TNF had a lower frequency of mutations compared with patients with IBD treated with anti-IL-12/23 and people in the healthy control group (Supplemental Figure 8C). Here, TNF is linked to inflammatory bowel disease.